Skip to main
RAPP
RAPP logo

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics Inc. has demonstrated significant momentum in its stock following the inaugural R&D Day and the disclosure of positive Phase 2a data, highlighting the efficacy of its lead product, RAP-219, in treating refractory focal onset epilepsy. The promising results from the first-in-patient data indicate a notably improved therapeutic window for RAP-219, bolstered by supportive preclinical and Phase 1 studies. Furthermore, the rapid and substantial seizure control exhibited by RAP-219 suggests that even a slight reduction in efficacy could lead to successful outcomes in future Phase 3 trials, potentially establishing a commercially competitive profile for the treatment.

Bears say

The negative outlook on Rapport Therapeutics Inc's stock is fundamentally supported by concerns regarding the reliability of Phase 2a efficacy results, as they may be overstated, casting doubt on the potential success in subsequent Phase 3 trials. Additionally, despite the high unmet need in epilepsy treatment, the commercial viability of Rapport's drugs could be significantly impacted by competitive pressures and unfavorable insurance coverage. Ultimately, these factors contribute to skepticism regarding the company's ability to effectively capitalize on its drug development efforts, raising concerns about future financial performance.

RAPP has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Strong Buy based on their latest research and market trends.

According to 5 analysts, RAPP has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.